Elesclomol (STA-4783)

Name: Elesclomol (STA-4783)
Brand: Selleck Chemicals
SKU: S1052
Rating: 5 (7 reviews)

For research use only. Not for use in humans.

Catalog No.S1052

7 publications

Elesclomol (STA-4783) Chemical Structure

Molecular Weight(MW): 400.5

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.

Selleck's Elesclomol (STA-4783) has been cited by 7 publications

Cell, 2017, 168(1-2):86-100

PubMed: 27916275 ( click the link to review the publication )

Osteoporos Int, 2018, 29(8):1917-1926

PubMed: 29860665 ( click the link to review the publication )

Oncol Rep, 2018, 40(2):635-646

PubMed: 29917168 ( click the link to review the publication )

Int J Biochem Cell Biol, 2017, 85:166-174

PubMed: 28259749 ( click the link to review the publication )

Int J Radiat Biol, 2017, 93(2):194-203

PubMed: 27600766 ( click the link to review the publication )

Oncotarget, 2016, 10.18632/oncotarget.10921

PubMed: 27486766 ( click the link to review the publication )

BMC Genomics, 2014, 15(1):263

PubMed: 24708151 ( click the link to review the publication )

4 Customer Reviews

BMC Genomics 2014 15(1), 263. Elesclomol (STA-4783) purchased from Selleck.

Treatment with elesclomol inhibits cancer cell growth and induces apoptosis by increasing ROS levels. a. Cell growth of SMOV2, IGROV1, and OVCA432 ovarian cancer cells treated with elesclomol in the presence or absence of the antioxidant NAC for 72 h. Cell growth was measured using the WST-1 assay and quantified relative to DMSO treated controls.

Oncotarget, 2016, 7(35):56933-56943. Elesclomol (STA-4783) purchased from Selleck.
Overexpression of GILZ favors oxidative cell death Dose-response of ROS production (HE staining) (A) or cell death (PI staining) (B) in indicated cells exposed toincreasing concentrations of elesclomol for 24 h (mean ± SD, n = 3, *p < 0.05). Alternatively, cells were treated with elesclomol for 24 h with or without pre-incubation with10 mM N-Acetyl Cysteine (NAC) for 12 h before HE staining (A) or PI staining (B) (mean ± SD, n = 3, *p < 0.05).

Int J Biochem Cell Biol, 2017, 85:166-174. Elesclomol (STA-4783) purchased from Selleck.

The proliferation of PC3 and LNCaP cells exposed to elesclomol at a range of concentrations for 48 h was assessed using MTT assay. Results are expressed as percentage of MTT absorbance of untreated cells at 0 h. p < .05 and p < .01 compared to untreated controls. Data are means ± SEM; n = 4.

Int J Radiat Biol, 2017, 93(2):194-203. Elesclomol (STA-4783) purchased from Selleck.

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Description

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.

Targets

HSP70 ^[1]
(Cell-free assay)

In vitro

Elesclomol significantly induces the expression of heat shock stress response genes and metallothionein genes, a signature transcription profile indicative of oxidative stress in Hs294T cells. Elesclomol (100 nM) rapidly induces Hsp70 RNA levels with a 4.8-fold increase at 1 hour and a 160-fold increase at 6 hours in Ramos Burkitt's lymphoma B cells in consistent with the intracellular ROS content which increases by 20% as early as 0.5 hour and 385% at 6 hours, and the induction of Hsp70 can be blocked by antioxidants N-acetylcysteine (NAC) and Tiron pretreatment. Elesclomol increases the number of early and late apoptotic cells with 3.7- and 11-fold through the induction of oxidative stress, which can be completely blocked by NAC, while having little effect on normal cells. ^[1] Elesclomol significantly inhibits the cell viability of SK-MEL-5, MCF-7, and HL-60 with IC50 of 110 nM, 24 nM and 9 nM, respectively. ^[2] Elesclomol induces copper-dependent ROS generation and cytoxicity in yeast. Instead of working through a specific cellular protein target, Elesclomol interacts with the electron transport chain (ETC), a biologically coherent set of processes occurring in the mitochondrion, to generate high levels of ROS within the organelle and consequently cell death. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
NOS-1 cell	MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NFy1ephKdmirYnn0bY9vKG:oIHj1cYFvKE6RUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKDNwNk\lMVA2KM7:TR?=	NVj1R5piW0GQR1XS
CAL-51 cell	MoT0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NFv6N3dKdmirYnn0bY9vKG:oIHj1cYFvKEODTD21NUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTJ4IH7N	NEjBbJVUSU6JRWK=
ABC-1 cell	MofoS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NWnUfYJjUW6qaXLpeIlwdiCxZjDoeY1idiCDQlOtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzZ3IH7N	MkHLV2FPT0WU
A2780 cell	M4eydmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NW\wZlgyUW6qaXLpeIlwdiCxZjDoeY1idiCDMke4NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPTl2IH7N	MXXTRW5ITVJ?
ES1 cell	M2jvNGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NHTzVJNKdmirYnn0bY9vKG:oIHj1cYFvKEWVMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUCuO\|Q6KG6P	M1y1enNCVkeHUh?=
HUTU-80 cell	MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NH35NYNKdmirYnn0bY9vKG:oIHj1cYFvKEiXVGWtPFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjd7MTDuUS=>	NYK3U3VDW0GQR1XS
NCI-H292 cell	M{ixXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NVHEbppDUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFI6OiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTBwOEi2JI5O	NYfLR3k6W0GQR1XS
NB69 cell	MmDHS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MXXJcohq[mm2aX;uJI9nKGi3bXHuJG5DPjliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkKyJI5O	NWi0VpZwW0GQR1XS
ES8 cell	NI\aVJFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NH;BOpJKdmirYnn0bY9vKG:oIHj1cYFvKEWVODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuN\|Ihdk1?	NH[2coFUSU6JRWK=
BCPAP cell	Mo\PS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	Ml[1TY5pcWKrdHnvckBw\iCqdX3hckBDS1CDUDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuN\|Qhdk1?	NYLlcGRHW0GQR1XS
T-24 cell	NFrmcFZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M3K2VGlvcGmkaYTpc44hd2ZiaIXtZY4hXC1{NDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuOVUhdk1?	M4iyUHNCVkeHUh?=
EW-16 cell	MlHnS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NHH0XYFKdmirYnn0bY9vKG:oIHj1cYFvKEWZLUG2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU43OSCwTR?=	NGTjeo1USU6JRWK=
OVCAR-5 cell	NHX2OnhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NWPIT5NNUW6qaXLpeIlwdiCxZjDoeY1idiCRVlPBVk02KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS56MzDuUS=>	M4P3OXNCVkeHUh?=
SF126 cell	M{\iZmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NGiybVZKdmirYnn0bY9vKG:oIHj1cYFvKFOIMUK2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU46PSCwTR?=	NX7vTVBvW0GQR1XS
KP-4 cell	Mnz4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MVTJcohq[mm2aX;uJI9nKGi3bXHuJGtRNTRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkG3JI5O	MVfTRW5ITVJ?
GAMG cell	MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MVrJcohq[mm2aX;uJI9nKGi3bXHuJGdCVUdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkWxJI5O	MXLTRW5ITVJ?
HOS cell	NXj1fG5iT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MUHJcohq[mm2aX;uJI9nKGi3bXHuJGhQWyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTJwNUOgcm0>	MmjoV2FPT0WU
CHL-1 cell	NWjOWFZnT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MWXJcohq[mm2aX;uJI9nKGi3bXHuJGNJVC1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mj64NUBvVQ>?	MoDUV2FPT0WU
AGS cell	MVfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NUDV[FRQUW6qaXLpeIlwdiCxZjDoeY1idiCDR2OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlg3KG6P	MlzZV2FPT0WU
MDA-MB-157 cell	NFuxUZBIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M2T1TmlvcGmkaYTpc44hd2ZiaIXtZY4hVUSDLV3CMVE2PyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTJwOUKgcm0>	MoTIV2FPT0WU
HSC-3 cell	NGSyelNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NGr6eIJKdmirYnn0bY9vKG:oIHj1cYFvKEiVQz2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4xOiCwTR?=	MXLTRW5ITVJ?
CAL-72 cell	MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MUDJcohq[mm2aX;uJI9nKGi3bXHuJGNCVC15MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUOuNFIhdk1?	MV;TRW5ITVJ?
NBsusSR cell	M4nydWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M3HoWGlvcGmkaYTpc44hd2ZiaIXtZY4hVkK\|dYPTVkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvOTNibl2=	MYTTRW5ITVJ?
ES7 cell	MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NILzNXZKdmirYnn0bY9vKG:oIHj1cYFvKEWVNzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUOuOVkhdk1?	MYrTRW5ITVJ?
H-EMC-SS cell	NYDyOIZFT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NELtSG1KdmirYnn0bY9vKG:oIHj1cYFvKEhvRV3DMXNUKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy54ODDuUS=>	MXfTRW5ITVJ?
NCI-H1703 cell	NU\4VXp1T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M1fYSGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixO\|A{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy54ODDuUS=>	M1fwXXNCVkeHUh?=
BHT-101 cell	MkDXS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MljpTY5pcWKrdHnvckBw\iCqdX3hckBDUFRvMUCxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{44OiCwTR?=	NH;MdXVUSU6JRWK=
SK-OV-3 cell	NXHMW49bT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NVXaeGdrUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3PWk0{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy55NTDuUS=>	NVra[pVFW0GQR1XS
EW-24 cell	MkTsS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	Mn;CTY5pcWKrdHnvckBw\iCqdX3hckBGXy1{NDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUOuPFMhdk1?	NYTYWohrW0GQR1XS
PSN1 cell	NW\z[IhOT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	Mke5TY5pcWKrdHnvckBw\iCqdX3hckBRW05zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mz64OEBvVQ>?	NHPibFdUSU6JRWK=
OVCAR-8 cell	M4GwV2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MWrJcohq[mm2aX;uJI9nKGi3bXHuJG9XS0GULUigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlk6KG6P	NX7l[Ys2W0GQR1XS
NCI-H1563 cell	NYfiW2pHT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M{[3V2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixOVY{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC5zMzDuUS=>	M1yzOXNCVkeHUh?=
SW756 cell	MWDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NYqzXHpFUW6qaXLpeIlwdiCxZjDoeY1idiCVV{e1OkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvOTNibl2=	MYjTRW5ITVJ?
A375 cell	MnnkS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NX3PZVUzUW6qaXLpeIlwdiCxZjDoeY1idiCDM{e1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE4yPCCwTR?=	NUC2S4oyW0GQR1XS
Ca9-22 cell	MXLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NEjKSIpKdmirYnn0bY9vKG:oIHj1cYFvKEOjOT2yNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvOjVibl2=	NWHS[ZJ7W0GQR1XS
SW1990 cell	MnXJS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NVP2OoRMUW6qaXLpeIlwdiCxZjDoeY1idiCVV{G5PVAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjN{IH7N	MkXxV2FPT0WU
ES4 cell	NF75S\|JIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NH3HV2xKdmirYnn0bY9vKG:oIHj1cYFvKEWVNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUSuN\|khdk1?	NGfJeJpUSU6JRWK=
HCE-T cell	MlLlS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NUT5XJE5UW6qaXLpeIlwdiCxZjDoeY1idiCKQ1WtWEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvPDVibl2=	NWficm5HW0GQR1XS
MOLT-16 cell	MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NFPDTXZKdmirYnn0bY9vKG:oIHj1cYFvKE2RTGStNVYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjV\|IH7N	NFX1fFBUSU6JRWK=
HSC-4 cell	MUPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	Mn\FTY5pcWKrdHnvckBw\iCqdX3hckBJW0NvNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUSuPEBvVQ>?	MXHTRW5ITVJ?
NCI-SNU-1 cell	M17K[2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M{m2fWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLWPOWU0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC56NjDuUS=>	M1\ZfnNCVkeHUh?=
EW-11 cell	NEXSPXpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M2W2NGlvcGmkaYTpc44hd2ZiaIXtZY4hTVdvMUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Mlkhdk1?	MWnTRW5ITVJ?
HT-1080 cell	MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NFT5eFhKdmirYnn0bY9vKG:oIHj1cYFvKEiWLUGwPFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01Njl7IH7N	MVvTRW5ITVJ?
MES-SA/Dx5 cells	MnTkR5l1d3SxeHnjbZR6KGG\|c3H5	MoDTR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWVUNVODL1T4OUBk\WyuczygTWM2OD13IH7N	MV6yN\|k{Pzl6MR?=
SW1710 cell	MofsS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	M{fJW2lvcGmkaYTpc44hd2ZiaIXtZY4hW1dzN{GwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU4yPiCwTR?=	M1XsSnNCVkeHUh?=
EW-1 cell	NHv5fnRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NYrsXnBCUW6qaXLpeIlwdiCxZjDoeY1idiCHVz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU4zPCCwTR?=	M{\m[XNCVkeHUh?=
BV-173 cell	M2XzRmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MWfJcohq[mm2aX;uJI9nKGi3bXHuJGJXNTF5MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUWuN\|khdk1?	MXjTRW5ITVJ?
TE-8 cell	MlnaS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MVHJcohq[mm2aX;uJI9nKGi3bXHuJHRGNThiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13LkSxJI5O	M2HJdHNCVkeHUh?=
G-401 cell	NVfMNpR2T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NVPMSmdnUW6qaXLpeIlwdiCxZjDoeY1idiCJLUSwNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPDNibl2=	MXXTRW5ITVJ?
KOSC-2 cell	M3H6U2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M3r5XGlvcGmkaYTpc44hd2ZiaIXtZY4hU0:VQz2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU41PSCwTR?=	NVK5c\|lnW0GQR1XS
HuCCT1 cell	MoPWS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NXXDXohyUW6qaXLpeIlwdiCxZjDoeY1idiCKdVPDWFEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjV{IH7N	MV;TRW5ITVJ?
FADU cell	M2L5bGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M4n0dmlvcGmkaYTpc44hd2ZiaIXtZY4hTkGGVTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUWuOlYhdk1?	NXPrOWxZW0GQR1XS
MHH-ES-1 cell	NHXXOWdIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M2OxTGlvcGmkaYTpc44hd2ZiaIXtZY4hVUiKLVXTMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjZ7IH7N	NXXxbYc2W0GQR1XS
ES3 cell	M{nCO2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MXrJcohq[mm2aX;uJI9nKGi3bXHuJGVUOyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTVwN{mgcm0>	MX7TRW5ITVJ?
OVCAR-4 cell	MofxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MYLJcohq[mm2aX;uJI9nKGi3bXHuJG9XS0GULUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21Mlg4KG6P	M37jSnNCVkeHUh?=
HD-MY-Z cell	M4fHV2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MVHJcohq[mm2aX;uJI9nKGi3bXHuJGhFNU2\LWqgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlkyKG6P	MWjTRW5ITVJ?
human JAR cell	MkPmS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	M3\IcGlvcGmkaYTpc44hd2ZiaIXtZY4hUkGUIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;NT65O{BvVQ>?	MnLjV2FPT0WU
A427 cell	NGXsc5pIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M1XQU2lvcGmkaYTpc44hd2ZiaIXtZY4hSTR{NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPU[uNFchdk1?	MWHTRW5ITVJ?
697 cell	M3jWSGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	Mn7UTY5pcWKrdHnvckBw\iCqdX3hckA3QTdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD14LkGzJI5O	MojQV2FPT0WU
OVCAR-3 cell	MWXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MlnTTY5pcWKrdHnvckBw\iCqdX3hckBQXkODUj2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok4zKG6P	NVO4WnhoW0GQR1XS
human NB14 cell	NGX6WnJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MorCTY5pcWKrdHnvckBw\iCqdX3hckBPSjF2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Nj62OEBvVQ>?	MWDTRW5ITVJ?
GB-1 cell	NVPScYdLT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NXrjVFVtUW6qaXLpeIlwdiCxZjDoeY1idiCJQj2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok44OSCwTR?=	NHjwUIxUSU6JRWK=
COR-L105 cell	MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MXzJcohq[mm2aX;uJI9nKGi3bXHuJGNQWi2OMUC1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok44PiCwTR?=	M36xV3NCVkeHUh?=
647-V cell	NF;wUZVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MUHJcohq[mm2aX;uJI9nKGi3bXHuJFY1Py2YIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Nj65JI5O	NIHGdVlUSU6JRWK=
human K5 cell	MUPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MWHJcohq[mm2aX;uJI9nKGi3bXHuJGs2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PyCwTR?=	NXrNbGNjW0GQR1XS
DMS-273 cell	M4TFTmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MVzJcohq[mm2aX;uJI9nKGi3bXHuJGROWy1{N{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23MlA3KG6P	NEDt[IFUSU6JRWK=
UM-UC-3 cell	Mo\wS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NH71WoNKdmirYnn0bY9vKG:oIHj1cYFvKFWPLWXDMVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04NjB4IH7N	MkDYV2FPT0WU
HEL cell	NVL2V\|VLT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M{jtO2lvcGmkaYTpc44hd2ZiaIXtZY4hUEWOIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Nz6wPEBvVQ>?	MWLTRW5ITVJ?
human KU-19-19 cell	NYnPdo1TT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M2m4e2lvcGmkaYTpc44hd2ZiaIXtZY4hU1VvMUmtNVkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04NjB7IH7N	NFvIZVBUSU6JRWK=
MC-IXC cell	NULNV3QxT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MkP6TY5pcWKrdHnvckBw\iCqdX3hckBOSy2LWFOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23MlE4KG6P	MYXTRW5ITVJ?
human H4 cell	M3mwSWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MW\Jcohq[mm2aX;uJI9nKGi3bXHuJGg1KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Py5{NTDuUS=>	NXPpOFJoW0GQR1XS
NUGC-3 cell	NVjkWFhMT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M2XzNGlvcGmkaYTpc44hd2ZiaIXtZY4hVlWJQz2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{4{OyCwTR?=	M3HqTHNCVkeHUh?=
CHP-212 cell	MnXVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	Ml\vTY5pcWKrdHnvckBw\iCqdX3hckBEUFBvMkGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{4{PCCwTR?=	MoHUV2FPT0WU
human SW982 cell	M3jLZmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NHPhflNKdmirYnn0bY9vKG:oIHj1cYFvKFOZOUiyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{41PCCwTR?=	M1X0e3NCVkeHUh?=
C-33-A cell	MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NHXnN2RKdmirYnn0bY9vKG:oIHj1cYFvKENvM{OtRUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvPThibl2=	M1:5XnNCVkeHUh?=
PC-3 cell	M3LheWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MXjJcohq[mm2aX;uJI9nKGi3bXHuJHBENTNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD15Lki5JI5O	MnSyV2FPT0WU
COLO-684 cell	M1\1Wmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MWLJcohq[mm2aX;uJI9nKGi3bXHuJGNQVE9vNki0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PU4zOSCwTR?=	NF\4RZhUSU6JRWK=
SNU-387 cell	MlHiS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	M3i1cWlvcGmkaYTpc44hd2ZiaIXtZY4hW06XLUO4O{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVkvPDlibl2=	NYHOT2RDW0GQR1XS
U251 cell	M{LkS2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NVnqe497UW6qaXLpeIlwdiCxZjDoeY1idiCXMkWxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PU45PiCwTR?=	NGW2UnpUSU6JRWK=
A673 cell	MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M2TPWmlvcGmkaYTpc44hd2ZiaIXtZY4hSTZ5MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGxMlYhdk1?	NFTscYJUSU6JRWK=
human T47D cell	NG\ye25Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NXvGcJlqUW6qaXLpeIlwdiCxZjDoeY1idiCWNEfEJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVYvPzlibl2=	NWXJU2VsW0GQR1XS
A549 cell	NIXBe3ZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NXnIUHRyUW6qaXLpeIlwdiCxZjDoeY1idiCDNUS5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVkvPiCwTR?=	NFeyVFBUSU6JRWK=
PC-14 cell	MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M2npOWlvcGmkaYTpc44hd2ZiaIXtZY4hWENvMUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yOE44OyCwTR?=	NHXKNGVUSU6JRWK=
A704 cell	MYTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MWHJcohq[mm2aX;uJI9nKGi3bXHuJGE4ODRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{Nz60OUBvVQ>?	NVzFTpVQW0GQR1XS
MCF7 cell	NY\DO3pMT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MV7Jcohq[mm2aX;uJI9nKGi3bXHuJG1ETjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1\|MT6zOkBvVQ>?	MnTsV2FPT0WU
PC3 cells	MUPGeY5kfGmxbjDhd5NigQ>?	NF7XdJZKdmirYnn0bY9vKG:oIGDET\|EudWWmaXH0[YQhSUuWIIDoc5NxcG:{eXzheIlwdiCjdDDUbJI{ODhicnXzbYR2\SCrbjDoeY1idiCSQ{OgZ4VtdHNiYomgSWxKW0FuIFnDOVA:OC5zMUOg{txO	NUXjcFE4OjF\|NEG2O\|U>
F-36P cells	NITme4RRem:uaX\ldoF1cW:wIHHzd4F6	M4XLbWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iRj2zOnAh[2WubIOsJGlEPTB;MD6yPEDPxE1?	M3\pUlIyOzRzNke1
OCI-AML2 cells	MVTQdo9tcW[ncnH0bY9vKGG\|c3H5	MU\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE:FST3BUWwzKGOnbHzzMEBKSzVyPUCuN\|Uh\|ryP	MoTJNlE{PDF4N{W=
K562 cells	NITQU2lRem:uaX\ldoF1cW:wIHHzd4F6	M4LiXWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iS{W2NkBk\WyuczygTWM2OD1zODFOwG0>	NVv0RZE1OjF\|NEG2O\|U>

... Click to View More Cell Line Experimental Data

In vivo

Although Elesclomol (25-100 mg/kg) as a single agent shows no antitumor activity in nude mouse xenograft models of human breast cancers (MDA435, MCF7 and ZR-75-1), lung cancer (RER) or lymphoma (U937), Elesclomol substantially enhances the efficacy of chemotherapeutic agents such as paclitaxel in these models, both in terms of tumor regression and extended survival of mice. ^[4]

Protocol

Cell Research:^[1]

- Collapse

Cell lines: Hs294T, HSB2, and Ramos
Concentrations: Dissolved in DMSO at a concentration of 10 mM, final concentrations ~500 nM
Incubation Time: 18, or 24 hours
Method: Cells are treated with various concentrations of Elesclomol for 18 or 24 hours. The level of intracellular ROS is monitored using the DCFDA probe, which emits a green fluorescence on oxidation. Cell death is determined by flow cytometry of cells double stained with Annexin V/FITC and propidium iodide (PI) using a Vybrant Apoptosis assay kit.
(Only for Reference)

Animal Research:^[4]

- Collapse

Animal Models: Female CD-1 nude mice bearing established MDA435 breast cancer xenograft tumors
Formulation: Dissolved in DMSO, and diluted in saline
Dosages: ~100 mg/kg
Administration: Intravenous injection
(Only for Reference)

References

[4] Gehrmann M. Curr Opin Investig Drugs, 2006, 7(6), 574-580.

- Collapse

Solubility (25°C)

In vitro	DMSO	80 mg/mL (199.75 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+40%PEG300+5%Tween80 +50%H2O For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Elesclomol (STA-4783) SDF

Molecular Weight	400.5
Formula	C₁₉H₂₀N₄O₂S₂
CAS No.	488832-69-5
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A
Smiles	CN(NC(=O)CC(=O)NN(C)C(=S)C1=CC=CC=C1)C(=S)C2=CC=CC=C2

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How can we use the compound for in vivo mouse studies?
Answer:
S1052 in 1% DMSO+30% polyethylene glycol+1% Tween 80 is a suspension, it is fine for oral administration. You can also dissolve S1052 in 0.5-1% CMC-Na solution and treat the mice by oral gavage.

HSP (e.g. HSP90) Signaling Pathway Map

Related HSP (e.g. HSP90) Products

PU-H71 ^New

PU-H71 is a potent and selective inhibitor of HSP90 with IC50 of 51 nM. Phase 1.
KNK437 ^New

KNK437 is a pan-HSP inhibitor, which inhibits the synthesis of inducible HSPs, including HSP105, HSP72, and HSP40.
VER155008 ^New

VER-155008 is a potent Hsp70 family inhibitor with IC50 of 0.5 μM, 2.6 μM, and 2.6 μM in cell-free assays for HSP70, HSC70, and GRP78, respectively, >100-fold selectivity over HSP90.
Tanespimycin (17-AAG)

Tanespimycin (17-AAG) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Phase 2.

Features:Displays very low toxicity toward normal cells.
Luminespib (NVP-AUY922)

Luminespib (AUY-922, NVP-AUY922) is a highly potent HSP90 inhibitor for HSP90α/β with IC50 of 13 nM /21 nM in cell-free assays, weaker potency against the HSP90 family members GRP94 and TRAP-1, exhibits the tightest binding of any small-molecule HSP90 ligand. Phase 2.
Ganetespib (STA-9090)

Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.
Alvespimycin (17-DMAG) HCl

Alvespimycin (17-DMAG) HCl is a potent HSP90 inhibitor with IC50 of 62 nM in a cell-free assay. Phase 2.

Features:A synthetic derivative Geldanamycin, with lower hepatotoxicity than parent antibiotic & higher potency and bioavailability than the similar derivative 17-AAG.
Geldanamycin

Geldanamycin is a natural existing HSP90 inhibitor with K_d of 1.2 μM, specifically disrupts glucocorticoid receptor (GR)/HSP association.
HSP990 (NVP-HSP990)

NVP-HSP990 (HSP990) is a novel, potent and selective HSP90 inhibitor for HSP90α/β with IC50 of 0.6 nM/0.8 nM.

Features:NVP-HSP990 is an orally available HSP90 inhibitor and is structurally distinct from other clinical HSP90 inhibitors.
Onalespib (AT13387)

Onalespib (AT13387) is a selective potent Hsp90 inhibitor with IC50 of 18 nM in A375 cells, displays a long duration of anti-tumor activity. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Elesclomol (STA-4783)